Read More: A study says people born between 1997 and 2012 developed one key psychological skill, and it may explain a lot about this generation<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nMechanical thrombectomy is one of the most important tools doctors have for these cases. A specialist uses a thin device to reach the blocked artery and pull out the clot, a bit like clearing a jammed pipe before the damage spreads.<\/p>\n\n\n\n
That procedure can be lifesaving, but it does not always restore full independence. Stroke<\/a> was the third leading cause of death and disability globally in 2021, according to the World Health Organization, so even modest improvements can matter for patients, families, and health systems.<\/p>\n\n\n\nThe hidden blockage<\/h2>\n\n\n\n
So why do some patients still struggle after the main clot is removed? The answer may lie in the brain\u2019s microcirculation, meaning the tiny blood<\/a> vessels that feed small areas of brain tissue.<\/p>\n\n\n\nArturo Ren\u00fa, the first author of the new work, described it this way: \u201cit is like reopening a highway while some side streets remain blocked.\u201d That image gets to the heart of the problem.<\/p>\n\n\n\n
The main road may be open, but blood still has to reach the neighborhoods. If small vessels remain clogged or sluggish, parts of the brain may continue to suffer, even after a technically successful thrombectomy.<\/p>\n\n\n\n
What the trial tested<\/h2>\n\n\n\n
The CHOICE-2 study was coordinated by Hospital Cl\u00ednic Barcelona and the August Pi i Sunyer Biomedical Research Institute, known as IDIBAPS. Neurologist \u00c1ngel Chamorro led the work with Ren\u00fa, and the trial involved 440 adults treated at 14 specialized hospitals in Spain.<\/p>\n\n\n\n
All patients had severe ischemic stroke and were successfully treated with mechanical thrombectomy. Afterward, they were randomly assigned to receive standard care alone or standard care plus intra-arterial alteplase, a drug designed to help dissolve remaining clots.<\/p>\n\n\n\n
The timing is the key twist. Alteplase has often been used before clot removal, but this trial tested whether giving it after the procedure could help clear the smaller vessels that thrombectomy cannot easily reach.<\/p>\n\n\n\n![\"A](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/06\/thrombectomy-alteplase-stroke-recovery-study.jpg\" "\\"\\"")
Clinical trial results indicate that administering alteplase directly into the brain artery after thrombectomy helps restore microcirculation.<\/figcaption><\/figure>\n\n\n\nBetter outcomes at 90 days<\/h2>\n\n\n\n
The results were clear enough to draw attention. After 90 days, 57.5% of patients who received the added drug had an excellent functional outcome, compared with 42.5% in the thrombectomy-only group.<\/p>\n\n\n\n
That does not mean the treatment is a magic fix. It means the combined approach gave a larger share of patients the chance to live with no disability or only minimal symptoms after a serious stroke.<\/p>\n\n\n\n
\n\n\nRead More: Helping clear the table may look like a kind gesture, but psychologists think it reveals something much deeper<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nBrain imaging also pointed in the same direction. Patients who received the added treatment had fewer areas with poor blood flow, suggesting that the drug may have helped restore circulation<\/a> where the smallest vessels were still struggling.<\/p>\n\n\n\nBuilt on earlier work<\/h2>\n\n\n\n
This trial did not come out of nowhere. The same research line began with the earlier CHOICE trial, published in 2022, which suggested that intra-arterial alteplase after thrombectomy could improve neurological outcomes.<\/p>\n\n\n\n
That first study was smaller and had limitations, so experts needed stronger evidence before changing practice. CHOICE-2 was designed to test the idea in a larger group and across more hospitals.<\/p>\n\n\n\n
The new results largely support the earlier signal. The 2022 CHOICE trial reported better 90-day outcomes with alteplase compared with placebo, but it also warned that the finding should be considered preliminary until replicated.<\/p>\n\n\n\n
What happens next<\/h2>\n\n\n\n
The findings may influence future stroke treatment guidelines, but doctors will still need to decide carefully which patients are most likely to benefit. In medicine, more treatment is not automatically one-size-fits-all.<\/p>\n\n\n\n
The JAMA paper also reported that death at 90 days was higher in the group that received alteplase, while serious brain bleeding was not significantly increased. <\/p>\n\n\n\n
That mixed safety picture is one reason researchers say more study is needed before the approach becomes routine everywhere.<\/p>\n\n\n\n
\n\n\nRead More: I tried a 10-minute mobility workout a trainer has done for over 20 years, and the twist is why it feels small in the moment but shows up everywhere in how your body moves<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nFor now, the message is both hopeful and cautious. Clearing the big clot can save brain tissue, but protecting recovery may also depend on what happens in the smallest vessels, the places doctors cannot see as easily.<\/p>\n\n\n\n
The main study has been published in JAMA<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"For many stroke patients, the biggest emergency is clear. A clot blocks blood flow to the brain, and doctors have … <\/p>\n
The hidden blockage<\/h2>\n\n\n\n
So why do some patients still struggle after the main clot is removed? The answer may lie in the brain\u2019s microcirculation, meaning the tiny blood<\/a> vessels that feed small areas of brain tissue.<\/p>\n\n\n\n Arturo Ren\u00fa, the first author of the new work, described it this way: \u201cit is like reopening a highway while some side streets remain blocked.\u201d That image gets to the heart of the problem.<\/p>\n\n\n\n The main road may be open, but blood still has to reach the neighborhoods. If small vessels remain clogged or sluggish, parts of the brain may continue to suffer, even after a technically successful thrombectomy.<\/p>\n\n\n\n The CHOICE-2 study was coordinated by Hospital Cl\u00ednic Barcelona and the August Pi i Sunyer Biomedical Research Institute, known as IDIBAPS. Neurologist \u00c1ngel Chamorro led the work with Ren\u00fa, and the trial involved 440 adults treated at 14 specialized hospitals in Spain.<\/p>\n\n\n\n All patients had severe ischemic stroke and were successfully treated with mechanical thrombectomy. Afterward, they were randomly assigned to receive standard care alone or standard care plus intra-arterial alteplase, a drug designed to help dissolve remaining clots.<\/p>\n\n\n\n The timing is the key twist. Alteplase has often been used before clot removal, but this trial tested whether giving it after the procedure could help clear the smaller vessels that thrombectomy cannot easily reach.<\/p>\n\n\n\n The results were clear enough to draw attention. After 90 days, 57.5% of patients who received the added drug had an excellent functional outcome, compared with 42.5% in the thrombectomy-only group.<\/p>\n\n\n\n That does not mean the treatment is a magic fix. It means the combined approach gave a larger share of patients the chance to live with no disability or only minimal symptoms after a serious stroke.<\/p>\n\n\n\n Brain imaging also pointed in the same direction. Patients who received the added treatment had fewer areas with poor blood flow, suggesting that the drug may have helped restore circulation<\/a> where the smallest vessels were still struggling.<\/p>\n\n\n\n This trial did not come out of nowhere. The same research line began with the earlier CHOICE trial, published in 2022, which suggested that intra-arterial alteplase after thrombectomy could improve neurological outcomes.<\/p>\n\n\n\n That first study was smaller and had limitations, so experts needed stronger evidence before changing practice. CHOICE-2 was designed to test the idea in a larger group and across more hospitals.<\/p>\n\n\n\n The new results largely support the earlier signal. The 2022 CHOICE trial reported better 90-day outcomes with alteplase compared with placebo, but it also warned that the finding should be considered preliminary until replicated.<\/p>\n\n\n\n The findings may influence future stroke treatment guidelines, but doctors will still need to decide carefully which patients are most likely to benefit. In medicine, more treatment is not automatically one-size-fits-all.<\/p>\n\n\n\n The JAMA paper also reported that death at 90 days was higher in the group that received alteplase, while serious brain bleeding was not significantly increased. <\/p>\n\n\n\n That mixed safety picture is one reason researchers say more study is needed before the approach becomes routine everywhere.<\/p>\n\n\n\n For now, the message is both hopeful and cautious. Clearing the big clot can save brain tissue, but protecting recovery may also depend on what happens in the smallest vessels, the places doctors cannot see as easily.<\/p>\n\n\n\n The main study has been published in JAMA<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" For many stroke patients, the biggest emergency is clear. A clot blocks blood flow to the brain, and doctors have … <\/p>\nWhat the trial tested<\/h2>\n\n\n\n
Better outcomes at 90 days<\/h2>\n\n\n\n
Read More: Helping clear the table may look like a kind gesture, but psychologists think it reveals something much deeper<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Built on earlier work<\/h2>\n\n\n\n
What happens next<\/h2>\n\n\n\n
Read More: I tried a 10-minute mobility workout a trainer has done for over 20 years, and the twist is why it feels small in the moment but shows up everywhere in how your body moves<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n